glp 1 gip tirzepatide The dual agonist action of on various organs. GLP-1: The Science Behind Tirzepatide: GLP-1

The low incidence of lactic acidosis reported in these studies is encouraging, though caution should still be taken when considering its use in patients with advanced liver failure

Ethics statement Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used

The following are the more likely side effects experienced with peptides: Injection site discomfort Changes in blood pressure, either increases or decreases depending on the peptide Fatigue and dizziness Hot or cold feelings Kidney and liver toxicity Potential toxicity to fetuses Abnormal heart rhythms Increased feelings of hunger Joint pain Tingling or numbness Water retention (this is a sign of overdose) Weight gain or loss Peptides with anabolic effects should not be considered for those with history or at risk of cancer Most side effects are localized and self-limiting

Legal Status of DSIP DSIP, like many experimental peptides, sits in a regulatory gray zone

Sarnak MJ

p = 0.001) (Supplementary Table 2)